Next-gen cell-penetrating antibodies for tumor targeting and RAD51 inhibition.

A research paper published in Oncotarget's Volume 15 on October 1, 2024, titled "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition," discusses the humanization of the monoclonal lupus-derived autoantibody 3E10 for tumor-specific targeting. Researchers from Yale University School of Medicine and Gennao Bio report that humanized variants of 3E10 show faster cell uptake and superior in vivo tumor targeting, with one variant retaining the ability to bind RAD51 and inhibit homology-directed repair. The study affirms the preservation of crucial biological properties essential for therapeutic efficacy in humanized 3E10. [Extracted from the article]